DF
ABBV icon

Donoghue Forlines’s AbbVie ABBV Stock Holding History

Donoghue Forlines’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Sell
7,314
-872
-11% -$193K 0.44% 93
2025
Q4 		$1.87M Buy
8,186
+1,157
+16% +$264K 0.58% 58
2025
Q3 		$1.63M Sell
7,029
-664
-9% -$135K 0.5% 59
2025
Q2 		$1.43M Sell
7,693
-9,791
-56% -$1.82M 0.41% 95
2025
Q1 		$3.66M Buy
17,484
+8,462
+94% +$1.65M 1.16% 12
2024
Q4 		$1.6M Buy
9,022
+1,131
+14% +$208K 0.54% 55
2024
Q3 		$1.56M Buy
7,891
+276
+4% +$51.5K 0.44% 54
2024
Q2 		$1.31M Buy
7,615
+118
+2% +$19.5K 0.37% 76
2024
Q1 		$1.37M Buy
7,497
+1,398
+23% +$241K 0.39% 79
2023
Q4 		$945K Sell
6,099
-216
-3% -$31.5K 0.3% 89
2023
Q3 		$941K Buy
6,315
+641
+11% +$94.1K 0.34% 91
2023
Q2 		$764K Buy
5,674
+2,322
+69% +$341K 0.24% 94
2023
Q1 		$534K Sell
3,352
-186
-5% -$28.4K 0.19% 127
2022
Q4 		$572K Sell
3,538
-1,132
-24% -$174K 0.2% 149
2022
Q3 		$627K Sell
4,670
-7,579
-62% -$1.09M 0.23% 79
2022
Q2 		$1.88M Sell
12,249
-3,877
-24% -$592K 0.49% 30
2022
Q1 		$2.61M Buy
16,126
+3,089
+24% +$449K 0.57% 29
2021
Q4 		$1.76M Sell
13,037
-1,732
-12% -$205K 0.3% 79
2021
Q3 		$1.59M Buy
14,769
+64
+0.4% +$7.31K 0.31% 83
2021
Q2 		$1.66M Buy
14,705
+340
+2% +$38.3K 0.31% 84
2021
Q1 		$1.55M Sell
14,365
-842
-6% -$90.1K 0.3% 83
2020
Q4 		$1.63M Buy
+15,207
New +$1.46M 0.31% 54
2020
Q1 		– Sell
-25,185
Closed -$2.23M – 61
2019
Q4 		$2.23M Buy
+25,185
New +$2.09M 0.35% 110
2018
Q1 		– Sell
-27,236
Closed -$2.63M – 143
2017
Q4 		$2.63M Sell
27,236
-188,545
-87% -$17.8M 0.2% 88
2017
Q3 		$19.2M Sell
215,781
-14,477
-6% -$1.1M 2.02% 7
2017
Q2 		$16.7M Buy
+230,258
New +$15.5M 1.89% 10

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Donoghue Forlines's ABBV Position: Q1 2026 in Review

Donoghue Forlines reduced its AbbVie (ABBV) stake by 11% in Q1 2026, selling an estimated $193K and leaving 7,314 shares worth $1.59M. The position accounts for 0.44% of the portfolio, ranked #93.

Donoghue Forlines first reported a position in ABBV in Q2 2017 and has held it in 26 quarters since. The position peaked at $19.2M in Q3 2017. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Donoghue Forlines held 7,314 shares of AbbVie worth $1.59M as of Q1 2026.
  • Donoghue Forlines sold 872 AbbVie shares in Q1 2026, an estimated $193K.
  • AbbVie made up 0.44% of Donoghue Forlines's portfolio in Q1 2026, its #93 holding.
  • Donoghue Forlines first reported a position in AbbVie in Q2 2017 and has held it in 26 quarters since.
  • Donoghue Forlines's AbbVie position peaked at $19.2M in Q3 2017.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Donoghue Forlines's 13F filing for Q1 2026, filed 13 May 2026.